Amy Stark to Genome-Wide Association Study
This is a "connection" page, showing publications Amy Stark has written about Genome-Wide Association Study.
Connection Strength
0.437
-
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
Score: 0.067
-
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
Score: 0.066
-
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
Score: 0.059
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.055
-
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
Score: 0.050
-
Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
Score: 0.020
-
Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
Score: 0.017
-
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
Score: 0.016
-
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
Score: 0.016
-
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
Score: 0.016
-
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
Score: 0.014
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.014
-
Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
Score: 0.013
-
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics. 2010 May; 20(5):327-37.
Score: 0.013